TransEnterix (TRXC) Collapses On FDA-Determination; ServiceNow (NOW) Surprises Wall Street


TransEnterix, Inc. (NYSEMKT:TRXC) said after the closing bell Wednesday that the FDA notified the company that its robotically enhanced laparoscopic surgical platform “SurgiBot System” does not meet the criteria for substantial equivalence, sending its shares down by more than 55% – to near 52-week low levels – in the extended session

TRXC stock closed at $4.74, down $0.03 (or -0.63%), and 2,569,013 of its shares exchanged hands during the day

TransEnterix, a medical device company, has 106.61M Shares Outstanding and TRXC stock one-year range is between $1.54 and $6.10 per share. At close on Wednesday, the company had a Market Capitalization of $505.33M



Shares of ServiceNow, Inc. (NYSE:NOW) climbed over 10% in after-hours trading Wednesday as the company delivered quarterly profit and revenue above Wall Street analysts’ expectations

For its first quarter 2016, ServiceNow posted revenues of $305.9 million, a 44% increase year over year, and non-GAAP net income of $14.5 million, or $0.09 per diluted share, compared to non-GAAP net income of $2.5 million, or per $0.01 per diluted share in the same period the prior year, exceeding the Capital IQ Consensus estimate of $0.07 on revenues of $300.83 million for the period

According to its business outlook, the company expects second quarter 2016 revenue to be in the range of $332 million to $335 million

NOW stock finished the regular session at $65.11, up $1.44 (or +2.26%), with a total volume of 2,800,899 shares traded during the day

ServiceNow, which offers service management solutions, has 160.79M Shares Outstanding, Market Capitalization (intraday) of $10.47B and NOW stock 52-week range is from $46.00 to $91.28 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at